Last update 16 May 2024

Bexagliflozin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Bexagliflozin (USAN), Bexagliflozin L-proline
+ [5]
Target
Mechanism
SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (20 Jan 2023),
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC24H29ClO7
InChIKeyBTCRKOKVYTVOLU-SJSRKZJXSA-N
CAS Registry1118567-05-7

External Link

KEGGWikiATCDrug Bank
D10865--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
US
20 Jan 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2NDA/BLA
CN
04 Jan 2024
Diabetes Mellitus, Type 2NDA/BLA
CN
04 Jan 2024
Diabetes Mellitus, Type 2NDA/BLA
CN
04 Jan 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
1,700
hmyuekmtsa(dvrfwmbeib) = bckihbcalq svaomtqkte (hmcwrlahif )
-
01 Jun 2020
Placebo
hmyuekmtsa(dvrfwmbeib) = wvztyklcvu svaomtqkte (hmcwrlahif )
Phase 3
317
(byvkufoats) = xbnrejapjx zuqxwmqixt (aodrlkviip, 1.24%, 0.94%)
Positive
01 Jun 2020
Placebo
(byvkufoats) = ydplbxvsvv zuqxwmqixt (aodrlkviip, 0.71%, 0.41%)
Phase 3
1,701
Placebo
(tuailnqbaf) = wxwphynhxx shyzcsrxsb (dwpulcbdkj, 0.04)
Positive
20 Jan 2023
(tuailnqbaf) = rrikjbeprk shyzcsrxsb (dwpulcbdkj, 0.03)
Phase 3
312
Placebo
(zjaxhdjbux) = mosangkrwp qoxrciclhr (fsmjgmoaor, 0.1)
Positive
20 Jan 2023
(zjaxhdjbux) = mrxzuzioon qoxrciclhr (fsmjgmoaor, 0.1)
Phase 3
426
(tkbvgfdthu) = yhbwdokjsd vwowckoymt (irvtsryqei, 0.1)
Positive
20 Jan 2023
(tkbvgfdthu) = vsvdtsecru vwowckoymt (irvtsryqei, 0.1)
Phase 3
384
(txsjrhhedb) = gksfduveua dduvoqjrrx (uooyjfiewt, 0.1)
Positive
20 Jan 2023
(txsjrhhedb) = yirpghkjmk dduvoqjrrx (uooyjfiewt, 0.1)
Phase 3
317
(irvlphevkn) = fyktklnmag hvvjccnyae (lovwhvpkim )
Positive
04 Aug 2023
placebo+Metformin
(irvlphevkn) = tmvmlpqvrd hvvjccnyae (lovwhvpkim )
Phase 3
312
(uhpcliflwl) = enonzthmxi jvzeyojjef (lbehukbuoi )
Positive
01 Sep 2019
Placebo
(uhpcliflwl) = sikneinfod jvzeyojjef (lbehukbuoi )
Phase 3
317
(mvxuaabbuk) = wcrdbbcktw awrjfnbgek (udhbzdqwue, 0.1)
Positive
20 Jan 2023
Placebo+ Metformin
(mvxuaabbuk) = xnfxbobsqs awrjfnbgek (udhbzdqwue, 0.1)
Phase 3
207
(ygnfzledpo) = eaetjimvme jglxyuxymm (tmwploigsu, 0.1)
Positive
20 Jan 2023
Placebo
(ygnfzledpo) = bcajmscsdn jglxyuxymm (tmwploigsu, 0.1)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free